pragma.vision Technology observatory & strategic foresight

Verification register Bio, Health & Neuro

Readiness verdict

CPTX2309 (Capstan in vivo CAR-T)

A dated reading of what is claimed, reported, and independently verified in the current evidence.

As of
2026-08-20
Revision
1
Method
v1.3.0

Current reading

Readiness band and full integer triple

AI-assisted assembly · derived results

Readiness band

Emerging

Primary summary from verified readiness

Confidence
80% · stale
Computed at
2026-08-20T10:53:24.16437+00:00
Claimed
30

Public ambition and stated capability

Reported
27

Observed practitioner reporting

Verified
20

Independently supported evidence

Gap
+10

Claimed leads verified

Evidence strength Strong

Decision

What the current evidence supports

Human editorial judgment · 2026-08-20

Too early to adopt

Why
Platform is strategically validated by a $2.1B AbbVie acquisition and Phase 1 dosing, but it has effectively zero published human clinical data; far too early for adoption despite very high industry attention.
Next
Watch for the first Phase 1 healthy-volunteer safety + B-cell-depletion readout (and any AbbVie pipeline disclosure post-acquisition) as the first real human signal

Constraints

Blockers

No named blocker is present in the current public projection.

Evidence summary

Derived counts

AI-assisted assembly

Total
9
Tier 1
0
Tier 2
7
Tier 3
2
Supports
5
Contradicts
1
Context
3
Latest observed
2026-02-11

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Revisions

Initial public reading

  1. 2026-07-19 Reading moved from emerging to emerging.

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.